Connor Clark & Lunn Investment Management Ltd. Takes $9.21 Million Position in DaVita Inc. $DVA

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, HoldingsChannel reports. The firm bought 41,386 shares of the company’s stock, valued at approximately $9,208,000.

Other hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp lifted its holdings in shares of DaVita by 831.4% during the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares during the period. Assenagon Asset Management S.A. raised its position in DaVita by 30.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock worth $9,963,000 after buying an additional 10,477 shares during the last quarter. SG Americas Securities LLC lifted its stake in DaVita by 27.4% during the 1st quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares during the period. LSV Asset Management boosted its holdings in shares of DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock valued at $106,426,000 after acquiring an additional 9,739 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of DaVita by 63.5% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after acquiring an additional 33,394 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DVA. Oppenheimer set a $220.00 price target on DaVita in a research report on Friday, August 7th. Truist Financial lowered their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, UBS Group boosted their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $221.75.

DaVita Stock Performance

DVA opened at $180.34 on Thursday. The company has a fifty day moving average of $213.07 and a two-hundred day moving average of $182.80. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The stock has a market capitalization of $11.51 billion, a price-to-earnings ratio of 14.76, a PEG ratio of 0.59 and a beta of 0.88.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Activity at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.90% of the stock is owned by company insiders.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.